Allied Funding Advisors LLC raised its place in Pfizer Inc. (NYSE:PFE – Free Report) by 3.7% in the course of the third quarter, HoldingsChannel.com studies. The agency owned 259,203 shares of the biopharmaceutical firm’s inventory after shopping for an extra 9,223 shares in the course of the quarter. Allied Funding Advisors LLC’s holdings in Pfizer have been price $7,501,000 as of its most up-to-date SEC submitting.
Various different hedge funds and different institutional buyers additionally lately made adjustments to their positions in PFE. FAS Wealth Companions Inc. raised its place in Pfizer by 1.3% in the course of the second quarter. FAS Wealth Companions Inc. now owns 26,306 shares of the biopharmaceutical firm’s inventory valued at $736,000 after buying an extra 342 shares within the final quarter. Sachetta LLC raised its stake in shares of Pfizer by 7.3% within the 2nd quarter. Sachetta LLC now owns 5,010 shares of the biopharmaceutical firm’s inventory valued at $140,000 after buying an extra 342 shares within the final quarter. Ironvine Capital Companions LLC lifted its holdings in Pfizer by 2.1% within the 1st quarter. Ironvine Capital Companions LLC now owns 16,953 shares of the biopharmaceutical firm’s inventory price $470,000 after buying an extra 353 shares over the last quarter. Safe Asset Administration LLC boosted its place in Pfizer by 0.6% in the course of the second quarter. Safe Asset Administration LLC now owns 58,328 shares of the biopharmaceutical firm’s inventory price $1,632,000 after buying an extra 353 shares in the course of the interval. Lastly, Patrick M Sweeney & Associates Inc. grew its holdings in Pfizer by 0.8% in the course of the second quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical firm’s inventory valued at $1,180,000 after buying an extra 355 shares over the last quarter. 68.36% of the inventory is owned by hedge funds and different institutional buyers.
Wall Avenue Analyst Weigh In
PFE has been the topic of a number of latest analyst studies. Barclays upped their worth goal on shares of Pfizer from $30.00 to $32.00 and gave the inventory an “equal weight” score in a report on Wednesday, July thirty first. Cantor Fitzgerald reaffirmed an “chubby” score and issued a $45.00 worth goal on shares of Pfizer in a analysis report on Thursday. StockNews.com reduce Pfizer from a “purchase” score to a “maintain” score in a analysis report on Tuesday. Wells Fargo & Firm raised their goal worth on Pfizer from $28.00 to $30.00 and gave the corporate an “equal weight” score in a report on Wednesday, July thirty first. Lastly, Daiwa Capital Markets upgraded Pfizer from a “impartial” score to an “outperform” score and upped their worth goal for the inventory from $28.00 to $34.00 in a report on Wednesday, August seventh. 9 analysis analysts have rated the inventory with a maintain score, six have issued a purchase score and one has issued a robust purchase score to the corporate. Based on MarketBeat.com, the corporate has a consensus score of “Average Purchase” and a mean goal worth of $34.54.
Test Out Our Newest Analysis Report on PFE
Pfizer Value Efficiency
Shares of NYSE:PFE traded up $0.24 throughout noon buying and selling on Friday, reaching $28.58. 28,786,884 shares of the corporate’s inventory have been exchanged, in comparison with its common quantity of 37,384,395. The corporate has a debt-to-equity ratio of 0.65, a fast ratio of 0.60 and a present ratio of 0.86. The corporate’s 50 day easy shifting common is $29.17 and its two-hundred day easy shifting common is $28.31. Pfizer Inc. has a 12 month low of $25.20 and a 12 month excessive of $33.92. The agency has a market capitalization of $161.95 billion, a PE ratio of -476.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67.
Pfizer (NYSE:PFE – Get Free Report) final launched its quarterly earnings knowledge on Tuesday, July thirtieth. The biopharmaceutical firm reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a optimistic return on fairness of 8.42% and a damaging internet margin of 4.66%. The corporate had income of $13.28 billion for the quarter, in comparison with the consensus estimate of $12.96 billion. Throughout the identical interval within the earlier yr, the enterprise earned $0.67 earnings per share. The corporate’s quarterly income was up 2.1% on a year-over-year foundation. Equities analysis analysts anticipate that Pfizer Inc. will submit 2.66 earnings per share for the present fiscal yr.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical merchandise in the US, Europe, and internationally. The corporate affords medicines and vaccines in varied therapeutic areas, together with cardiovascular metabolic, migraine, and ladies’s well being below the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin household manufacturers; infectious illnesses with unmet medical wants below the Prevnar household, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba manufacturers; and COVID-19 prevention and therapy, and potential future mRNA and antiviral merchandise below the Comirnaty and Paxlovid manufacturers.
Learn Extra
Wish to see what different hedge funds are holding PFE? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Obtain Information & Rankings for Pfizer Every day – Enter your e mail handle under to obtain a concise each day abstract of the most recent information and analysts’ rankings for Pfizer and associated firms with MarketBeat.com’s FREE each day e mail publication.